USPTO Examiner YOO SUN JAE - Art Unit 1621

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19265483CABOZANTINIB COMPOSITIONS AND METHODS OF USEJuly 2025August 2025Allow200NoNo
19184766CABOZANTINIB COMPOSITIONS AND METHODS OF USEApril 2025October 2025Allow601NoNo
19184838CABOZANTINIB COMPOSITIONS AND METHODS OF USEApril 2025November 2025Allow701NoNo
19184689CABOZANTINIB COMPOSITIONS AND METHODS OF USEApril 2025December 2025Allow801NoNo
18938926CABOZANTINIB COMPOSITIONS AND METHODS OF USENovember 2024May 2025Allow611YesNo
18771270Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives ThereofJuly 2024December 2025Abandon1711NoNo
18643330PEPTOID-BASED INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE (PRMT) FAMILYApril 2024April 2025Allow1211NoNo
18643948METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONESApril 2024February 2026Allow2211NoNo
18630017Fluorogenic Probe Using a Mislow-Evans Rearrangement for Real-Time Imaging of Hydrogen PeroxideApril 2024October 2025Allow1821NoNo
18618379SALT OF AN AMINOPYRIDINE DERIVATIVE COMPOUND, A CRYSTALLINE FORM THEREOF, AND A PROCESS FOR PREPARING THE SAMEMarch 2024July 2025Allow1521YesNo
18617723NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERSMarch 2024April 2025Allow1301NoNo
18613641Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)March 2024January 2026Allow2210NoNo
18612849COMPOUNDS AND THEIR USEMarch 2024April 2025Allow1301NoNo
18605248CDK2 INHIBITORSMarch 2024September 2025Allow1801NoNo
18421849SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTJanuary 2024June 2025Allow1701YesNo
18414865COMPOSITIONS AND USES THEREOFJanuary 2024January 2026Allow2422NoNo
18545953COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERSDecember 2023November 2025Allow2300NoNo
18545932COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERSDecember 2023July 2024Allow700YesNo
18520156SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTNovember 2023December 2024Allow1312YesNo
18509586TARGETING THE TLK1/NEK1 AXIS IN PROSTATE CANCERNovember 2023July 2025Allow2011YesNo
18289449ORGANOMETALLIC COMPOUND AND APPLICATION THEREOFNovember 2023February 2026Allow2700NoNo
18501930NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASESNovember 2023October 2025Abandon2311NoNo
18289437ORGANOMETALLIC COMPOUND AND APPLICATION THEREOFNovember 2023January 2026Allow2700YesNo
18385025NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORSOctober 2023November 2024Allow1201NoNo
18482143Inhibitors of RAD52 Recombination Protein and Methods Using SameOctober 2023August 2025Abandon2211NoNo
18476050SOLID FORMS AND COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOFSeptember 2023August 2024Allow1110NoNo
18465768COMPOSITIONS, KITS, AND METHODS TO INDUCE ACQUIRED CYTORESISTANCE USING STRESS PROTEIN INDUCERSSeptember 2023April 2024Allow711NoNo
18234608PLASMA KALLIKREIN INHIBITORS AND USES THEREOFAugust 2023August 2024Allow1201NoNo
18365392BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USEAugust 2023November 2024Abandon1601NoNo
18365044MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USEAugust 2023January 2025Abandon1701NoNo
18351283TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORSJuly 2023April 2025Allow2111NoNo
18213082ANTITUMORAL COMPOUNDSJune 2023March 2025Allow2111NoNo
18332566TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USEJune 2023May 2024Allow1101NoNo
18254550SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATEMay 2023March 2026Abandon3401NoNo
18308037ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASEApril 2023July 2025Allow2620NoNo
18136734THERAPEUTIC COMPOUNDS AND COMPOSITIONSApril 2023May 2025Abandon2501NoNo
18136661PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOFApril 2023August 2024Allow1601NoNo
18133060FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIAApril 2023December 2024Allow2011NoNo
18124427ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERSMarch 2023April 2024Allow1311NoNo
18181099ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOFMarch 2023July 2024Allow1621NoNo
18172742BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOFFebruary 2023September 2024Abandon1801NoNo
18112402CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAMEFebruary 2023January 2025Allow2311NoNo
18166178CDK2 INHIBITORSFebruary 2023February 2024Allow1221NoNo
18018359COMPOUNDSJanuary 2023March 2026Allow3711NoNo
18099875CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAMEJanuary 2023July 2024Allow1801NoNo
18006068PROCESS FOR PREPARING AMINOFURANESJanuary 2023January 2026Allow3611NoNo
18004837MIXTURE OF LEVONOGESTREL AND ETHINYLESTRADIOL AS CONTROL FOR BARK INSECTSJanuary 2023December 2025Allow3510YesNo
18002004ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORSDecember 2022December 2025Abandon3601NoNo
17928519Nitrosation Reagents and MethodsNovember 2022June 2025Allow3000NoNo
17999545DRUG-LIKE MOLECULES AND METHODS FOR THE THERAPEUTIC TARGETING OF VIRAL RNA STRUCTURESNovember 2022January 2026Abandon3701NoNo
18049652PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORSOctober 2022May 2024Allow1811NoNo
18046011MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USEOctober 2022May 2024Abandon1901NoNo
17959920ENANTIOMERS OF A2-73, ANALOGUES, AND SIGMA AGONIST ACTIVITYOctober 2022September 2024Allow2311YesNo
17953935CRYSTALLINE SALTS OF PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITORSeptember 2022September 2023Allow1201NoNo
17907174NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORSSeptember 2022February 2026Allow4011NoNo
179071761,3-DIHYDRO-2H-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORSSeptember 2022February 2026Allow4111NoNo
17930695SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTSeptember 2022January 2025Abandon2821YesNo
17929656METHODS OF TREATING GLIOBLASTOMASeptember 2022January 2024Abandon1701NoNo
17908362A PROCESS FOR PREPARATION OF 3,6-DICHLOROCYANO PYRAZINE, 3,6-DIOXOPIPERAZINE DERIVATIVES AND PRODUCTION OF FAVIPIRAVIR THEREOFAugust 2022August 2025Abandon3501NoNo
17896767EBNA1 Inhibitor Crystalline Forms, and Methods of Preparing and Using SameAugust 2022June 2024Allow2111NoNo
17894700ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAMEAugust 2022November 2023Allow1501NoNo
17816855OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORSAugust 2022August 2024Allow2411NoNo
17816281CXCR7 INHIBITORS FOR THE TREATMENT OF CANCERJuly 2022March 2025Abandon3121NoNo
17870573COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERSJuly 2022October 2023Allow1501NoNo
17634361NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUNDJuly 2022August 2025Abandon4201NoNo
17777428BICYCLIC COMPOUND USED AS SELECTIVE ANDROGEN RECEPTOR MODULATORJuly 2022August 2025Abandon3901NoNo
17858233PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AGING-RELATED DISEASESJuly 2022November 2024Abandon2911NoNo
17810367COMPOUNDS AND THEIR USEJuly 2022March 2024Allow2011NoNo
17790330CYCLOCARBONATE GROUP-CONTAINING (METH)ACRYLATE MONOMER AND POLYMERJune 2022November 2025Allow4111YesNo
17855414METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONESJune 2022January 2024Allow1811NoNo
17850453CDK2 INHIBITORSJune 2022January 2024Allow1811NoNo
17845534DIACYLGLYCEROL KINASE MODULATING COMPOUNDSJune 2022January 2024Allow1911NoNo
17845142BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORSJune 2022February 2024Allow2001NoNo
17845499Method of Manufacture for Liquid Cannabinoids, and Modified CBD Oil CompositionJune 2022January 2024Abandon1901NoNo
17844921DIACYLGLYCEROL KINASE MODULATING COMPOUNDSJune 2022February 2024Allow2011NoNo
17843197COMPOSITIONS PROVIDING SLOW RELEASE OF CAFFEINEJune 2022April 2025Allow3412NoNo
17842158Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives ThereofJune 2022November 2024Abandon2921NoNo
17840957BCL-2 INHIBITORSJune 2022January 2024Allow1911NoNo
17784239TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIESJune 2022September 2025Allow4011NoNo
17828643BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITYMay 2022September 2024Abandon2712YesNo
17826289ORAL AQUEOUS SUSPENSION FORMULATION COMPRISING CARBAMATE COMPOUNDMay 2022October 2024Allow2921NoNo
177444325,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASESMay 2022July 2024Abandon2621NoNo
17776952COMPOUNDS AND USES THEREOFMay 2022November 2024Allow3011NoNo
17738872HETEROCYCLIC PROLINAMIDE DERIVATIVESMay 2022May 2024Abandon2512NoNo
17736057TIMOSAPONIN COMPOUNDSMay 2022October 2024Allow3012NoNo
17661274USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND AGING IN THE SKINApril 2022November 2023Abandon1801NoNo
17771344Non-Coordinating Anion Activators Containing a Cation with Long Chain Alkoxy FunctionalizationApril 2022September 2025Allow4111NoNo
17755100Process for preparing glycerol carbonate (meth)acrylateApril 2022June 2025Allow3800NoNo
17726120METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S)April 2022April 2025Allow3521NoNo
17659104CLEANING COMPOSITIONApril 2022October 2025Abandon4201NoNo
17716645P53-DESTABILIZING PROTEIN ASSOCIATED WITH PROTO-ONCOGENE STEMNESS AS A THERAPEUTIC TARGET AND INHIBITORS THEREOF FOR USE IN TREATMENT OF CANCERApril 2022March 2024Allow2411NoNo
17754703QUINOLONE CARBOXYLIC DERIVATIVESApril 2022February 2025Allow3500NoNo
17766601COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOFApril 2022January 2026Allow4621NoNo
17713512APPLICATION OF HONOKIOL AND MAGNOLOL IN PREPARATION OF MCR-1 ENZYME INHIBITORApril 2022February 2026Abandon4611NoNo
17714114Antitumoral CompoundsApril 2022January 2023Allow911NoNo
17763073SILICONE DROPLETSMarch 2022September 2025Abandon4101NoNo
17761868AN IMPROVED PROCESS FOR 4-(HYDROXYMETHYL)-5-METHYL-1,3-DIOXOL-2-ONEMarch 2022April 2025Allow3710NoNo
17697655SALT OF AN AMINOPYRIDINE DERIVATIVE COMPOUND, A CRYSTALLINE FORM THEREOF, AND A PROCESS FOR PREPARING THE SAMEMarch 2022September 2023Allow1801YesNo
17655262FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOFMarch 2022September 2024Abandon3021YesNo
17760878SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERSMarch 2022January 2025Abandon3401NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YOO, SUN JAE.

Strategic Value of Filing an Appeal

Total Appeal Filings
13
Allowed After Appeal Filing
6
(46.2%)
Not Allowed After Appeal Filing
7
(53.8%)
Filing Benefit Percentile
74.8%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner YOO, SUN JAE - Prosecution Strategy Guide

Executive Summary

Examiner YOO, SUN JAE works in Art Unit 1621 and has examined 313 patent applications in our dataset. With an allowance rate of 84.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.

Allowance Patterns

Examiner YOO, SUN JAE's allowance rate of 84.7% places them in the 60% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by YOO, SUN JAE receive 1.70 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by YOO, SUN JAE is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +19.4% benefit to allowance rate for applications examined by YOO, SUN JAE. This interview benefit is in the 62% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 29.7% of applications are subsequently allowed. This success rate is in the 57% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 45.5% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 78.8% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 30.4% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.1% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.